ADA Standards of Medical Care in Diabetes 2022 – what’s new?

Česká verzia

Authors: Jan Škrha jr.
Authors place of work: 3. interní klinika 1. LF UK a VFN, Praha
Published in the journal: Vnitř Lék 2022; 68(2): 85-88
Category: Main Topic

Summary

A selection of the most important changes in recent ADA guidelines on diabetes screening, diagnosis, pharmacotherapy, or technologies in 2022.

Keywords:

diabetes – technology – pharmacotherapy – guidelines

Zdroje

1. Committee ADAPP. Summary of Revisions: Standards of Medical Care in Diabetes—2022. Diabetes Care 2021; 45(Supplement_1): S4-S7.

2. Davies MJ, D’Alessio DA, Fradkin J et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41(12): 2669-2701.

3. Buse JB, Wexler DJ, Tsapas A et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020; 43(2): 487-493.

4. Committee ADAPP. 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022. Diabetes Care 2021; 45(Supplement_1): S175-S184.

5. Committee ADAPP. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022. Diabetes Care 2021; 45(Supplement_1): S144-S174.

6. Committee ADAPP. 7. Diabetes Technology: Standards of Medical Care in Diabetes—2022. Diabetes Care 2021; 45(Supplement_1): S97-S112.